Sangamo Therapeutics (SGMO) Raised to “Strong-Buy” at BidaskClub

BidaskClub upgraded shares of Sangamo Therapeutics (NASDAQ:SGMO) from a buy rating to a strong-buy rating in a research note issued to investors on Wednesday morning.

A number of other research firms have also recently commented on SGMO. Guggenheim cut shares of Sangamo Therapeutics from a buy rating to a neutral rating and set a $18.00 target price for the company. in a research note on Friday, November 9th. ValuEngine cut shares of Sangamo Therapeutics from a strong-buy rating to a buy rating in a research note on Wednesday, January 2nd. Wedbush set a $11.00 target price on shares of Sangamo Therapeutics and gave the stock a hold rating in a research note on Monday, November 19th. Zacks Investment Research cut shares of Sangamo Therapeutics from a hold rating to a sell rating in a research note on Wednesday, October 10th. Finally, JPMorgan Chase & Co. cut shares of Sangamo Therapeutics from an overweight rating to a neutral rating and lowered their target price for the stock from $35.00 to $11.00 in a research note on Wednesday, November 14th. One research analyst has rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of Buy and an average price target of $18.83.

NASDAQ SGMO opened at $11.38 on Wednesday. The company has a current ratio of 6.32, a quick ratio of 6.32 and a debt-to-equity ratio of 0.07. The stock has a market cap of $1.12 billion, a price-to-earnings ratio of -16.26 and a beta of 2.72. Sangamo Therapeutics has a one year low of $9.00 and a one year high of $27.50.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.02. Sangamo Therapeutics had a negative net margin of 88.78% and a negative return on equity of 22.06%. The business had revenue of $23.56 million for the quarter, compared to analysts’ expectations of $26.96 million. During the same period last year, the business earned ($0.15) EPS. The company’s revenue was up 99.5% compared to the same quarter last year. On average, equities research analysts expect that Sangamo Therapeutics will post -0.72 EPS for the current year.

In other Sangamo Therapeutics news, VP Edward R. Conner sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, January 7th. The shares were sold at an average price of $12.33, for a total transaction of $61,650.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 30,000 shares of company stock valued at $364,800 over the last three months. 1.20% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Mount Yale Investment Advisors LLC raised its position in Sangamo Therapeutics by 2,202.8% during the 2nd quarter. Mount Yale Investment Advisors LLC now owns 8,359 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 7,996 shares during the last quarter. NumerixS Investment Technologies Inc purchased a new position in shares of Sangamo Therapeutics during the 2nd quarter valued at approximately $125,000. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Sangamo Therapeutics during the 3rd quarter valued at approximately $182,000. Bourgeon Capital Management LLC purchased a new position in shares of Sangamo Therapeutics during the 3rd quarter valued at approximately $197,000. Finally, Advisors Asset Management Inc. increased its holdings in shares of Sangamo Therapeutics by 130.0% during the 2nd quarter. Advisors Asset Management Inc. now owns 12,020 shares of the biopharmaceutical company’s stock valued at $301,000 after purchasing an additional 6,793 shares in the last quarter. 63.13% of the stock is owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

Featured Story: How much can an individual set aside as a catch-up contribution?

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply